
$\checkmark$ Revise synthesis, regulations \& dysregulations of corticosteroids.
$\checkmark$ Classify available natural vs synthetic glucocorticoides; whether systemic or topical; expanding on their properties \& indications .
$\checkmark$ Contrast their different ADRs \& methods of prevention or treatment Focus on therapeutic roles of mineralocorticoids \& relevant mechanism of action.
$\checkmark$ Hint on drugs antagonizing corticosteroid action.

slide

## Corticosteroids

## Glucocorticoids [GC]

| Synthesis in | Zona Fasciculata |
| :--- | :--- |
| Released as | -Cortisol <br> -Cortisone <br> -Corticosterone |
| Regulated by |  <br> catecholamines. |

Function -Control carbohydrate, fat \& protein metabolism. -anti-inflammatory \& immunosuppressants

Deficiency Addison's disease
Increased Cushing's syndrome

## Mineralocorticoids [MC]

Zona Glomeruloza
Aldosterone

Potassium - ACTH (little control)
dopamine- atrial natriuretic peptide (ANP)

- Angiotensin II - neuropeptides .

Control water \& electrolyte homeostasis (acute function)

Hyponatremia, hyperkalemia, acidosis, wasting, hypotension \& shock.

Conn's syndrome:
Hyperaldosteronism, Hypernatremiam, Hypervolemiam Hypertension \& Hypokalemia.

## Notes

## 1-Addison's disease

Hyponatremia, hyperkalemia, hypoglycemia, progressive weakness \& fatigue, low blood pressure, depression, anorexia \& loss of weight, skin hyperpigmentation. 2-Addisonian Crisis ( EMERGENCY)
$\uparrow \uparrow$ symptoms $\rightarrow$ fever, confusion sever vomiting, diarrhea, abdominal pain \& shock.

## Regulation of Glucocorticoids



Regulation of Mineralocorticoid


## Pharmacology Of Exogenous Glucocorticoids

*Many types of Exogenous Glucocorticoids but most important are:
-Cortisol, Cortisone, Hydrocortisone
*Mechanism:
-Glucocorticoids binds to its receptor on by two ways :
1-Cytosolic Glucocorticoids receptor:
Mediates Genomic Action (Slow Process)
A-Expression of proteins $\rightarrow$ Anti-inflammatory Effects
e.g. Lipocortin ,which suppress phospholipase A2 >> inhibit PG \& leukotiene.

B-Repression of proteins $\rightarrow$ Pro-inflammatory Effects
prevent (AP-1) from binding to it's receptor >> no pro-inflammatory mediators (IL-2,6...ECT) .

## 2-Membranous Glucocorticoids receptor:

mediates NON-GENOMIC Action (rapid process) $\rightarrow$ cross talks with GP coupled receptors $\rightarrow$ alter Ca, cAMP, their downstream kinases (PKA \& PKC) $\rightarrow$ rapidly exert anti-inflammatory effects \& shut down proinflammatory effects $\rightarrow$ rapid process needs minutes-hrs
slide doctor's note
important
explanation

## Pharmacological actions

## 1. On METABOLISM

| CHO | Proteins | Fats | Calcium |
| :---: | :---: | :---: | :---: |
| $\downarrow$ glucose utilization. <br> 个gluconeogenesis <br> leading to <br> (hyperglycaemia) | $\downarrow$ anabolism <br> $\uparrow$ catabolism leading to <br> (Negative nitrogen balance with muscle wasting <br> - $\uparrow$ uric a. production Osteoporosis. <br> - Retardation of growth in children. <br> - Skin atrophy + capillary fragility $\rightarrow$ bruising and stria) | fat deposition on shoulders, face and abdomen. | $\uparrow$ urinary excretion <br> $\uparrow \downarrow$ absorption from intestine (antivitamin D action). |
| 2. On INFLAMMATORY \& IMMUNE RESPONSE |  |  |  |

$\downarrow$ vascular permeability so $\downarrow$ edema \& redundancy of soft tissues
$\downarrow$ release \& synthesis of inflammatory mediators so -ve PLA2 \& -ve AA \& LTs pathways
$\downarrow$ antigen antibody reaction so $\downarrow$ mast cell degranulation \& transmitter release
$\downarrow$ infiltration \& activity of inflammatory cells by $\downarrow$ cytokines \& chemokine production
$\downarrow$ Complement formation

## 3. ON HYPOTHALAMIC-PITUITARY-ADRENAL AXIS

Occurs with high doses \& long periods of treatment, Sudden withdrawal of corticosteroids produce a state of adrenocortical insufficiency. (-ve feed back mechanism )

## 4. Others

Euphoria or psychotic states: may occur (probably due to CNS electrolyte changes)

| slide | doctor's note | important | explanation |
| :--- | :--- | :--- | :--- | :--- |

## Pharmacokinetics

## 1. Absorption

- Most preparations are effective orally and Parentral forms are also available.
- Can get absorbed systemically when given at local sites (e.g. skin, respiratory tract, conjunctival sac, synovial spaces etc.)


## 2. Distribution

- $\mathbf{9 0 \%}$ or more of cortisol in plasma is transported by reversible binding to Corticosteroids Binding Globulin (CBG) \& to albumin

Corticosteroids compete with each other on CBG (Glucocorticoids bind with high affinity \& Mineralocorticoids bind with low affinity)

- Only the unbound free form is active \& can enter cells by diffusion


## 3. Metabolism \& Excretion

- are metabolized by the liver \& excreted as soluble sulphates in the urine
- Some preparations transform to active form in liver

Cortisone $\rightarrow$ Hydrocortisone
Prednisone $\rightarrow$ Prednisolone

## 4. Dosage Schedule

Time of administration of GCs $\rightarrow$ specially on prolonged use you should follow natural circadian rhythm i.e. early morning to minimize hypothalamo-pituitary-adrenal axis impairment and Better if administered on alternate days

## Classification According To t 1/2 \& Method Of Administration

|  | Short Acting (t1/2 < 12h) . Inter | Intermediate Acting (t1/2=12-36h) | Long Acting (t1/2 >36h) |
| :---: | :---: | :---: | :---: |
|  | $\uparrow$ Na retaining property .¢ anti <br> some | $\uparrow$ anti-inflammatory action, with some Na retaining . | Anti-inflammatory, No Na retention . |
|  | 1-Cortisol *IM / IV * 1-Pred <br> (EMERGENCY) intrar <br> 2-Cortisone *IM* 2-Tria <br> (not in liver disease) intrar <br>  3-Pre <br>  4-Me | ```1-Prednisolone *IM, intrarticular* 2-Triamcinolone *IM, intrarticular* (No Na retention) 3-Prednisone 4-Methyl- "``` | 1-Dexamethasone <br> [Fluorinated] * IM / IV * <br> 2-Betamethasone <br> [Fluorinated] * IM / IV * |
|  | 1-Fluticasone <br> 2-Budesonide <br> 3-Beclomethasone |  |  |
|  | Potent | Moderate | Mild |
|  | 1-Beclomethasone *cream* <br> 2-Triamcinolone actonide *ointment* <br> 3-Betamethasone | 1-Mometasone <br> *ointment* <br> 2-Fluticasone *cream* <br> 3-Fluocinolone actonide <br> 4-Hydrocortisone acetate | 1-Hydrocortisone acetate *ointment* |

On sensitive skin (face, babies) only apply milde-moderate steroid as creams

| slide | doctor's note | important | explanation |
| :--- | :--- | :--- | :--- |

## INDICATIONS

## 1. Hormone replacement therapy

## 1. ADRENAL INSUFFECIENCY

Addisonian Crisis *acute* (shock)<br>1-Parental Cortisol (hydrocortisone) $\rightarrow 100$<br>mg IV / every 6-8 hrs until patient is stable.<br>Dose $\Rightarrow$ gradually reduced

2-Fluids and electrolytes should be corrected.
3 -Treatment of precipitating factors.

## Addison's Disease *chronic*

1-Cortisol (orally) + fludrocortisone (orally)
And Dexamethasone could be given on prolonged use

2-Doses must be increased in stress to
prevent development of Addisonian crisis
3- Doses should follow circadian rhythm

## 2. CUSHING'S SYNDROME

1-in Diagnoses Dexamethasone
suppression test.

2-in Treatment Cortisol Temporally administered AFTER surgical removal of pituitary / adrenal / corticosteroid secreting tumors.

## 2. Anti-inflammatory \& immunosuppressant

## We use :

1-Prednisolone
1-Severe allergic reactions e.g. serum sickness,angioneurotic edema
2-Diseases of allergic origin bronchial asthma, rhinitis, conjunctivitis, eczema \& many other atopic \& proliferative skin diseases 3-Autoimmune disorders; rheumatoid arthritis, inflammatory bowel disease systemic lupus erythrematosus, nephrotic syndrome
4-Organ transplantation; kidney, cardiac, bone marrow ( $\downarrow$ rejection) 5-Acute gout (resistant) to other drugs
5-Blood dyscrasias hemolytic anemia, thrombocytopenic purpura, agranulocytosis

| 3. Others | We use : |
| :--- | :---: |
| 1-Raised intracranial pressure | 1-Dexamethasone |
| 2-In neoplastic diseases With cytotoxic drugs $\rightarrow$ as in Hodgkin's disease, acute lymphocytic | If water retention is undesirable |
| leukemia /// 1ry or 2ndry neoplasms in the brain \& postoperative to brain surgery $\rightarrow$ tedema $/ / /$ In antiemetic regimens $\rightarrow$ prevent $/$ cure |  |
| emesis of chemotherapy |  |
| 3-Suppress excess ACTH production |  |



## 1- How to avoid?



-Hyperglycemia, glycosuria, diabetes mellitus, Muscle wasting .
use better fluorinated preparations
-Growth retardation $\rightarrow$ short stature.
-Fat redistribution \& abnormal deposition.
-Hypertension, oedema, Na retention, Hypokalaemia .
-Osteoporosis .
-Menstrual irregularities.
-Psychiatric disorders.
-Impairment of defense mechanism.
-Peptic ulcer specially if with NSAIDs.
-Skin, acne, striae, hirsutism.

## -Avascular necrosis of head of femur.

Specific to glucocorticoid. -Ocular toxicity $\rightarrow$ glaucoma \& cataract.
-Skin $\rightarrow$ infection, atrophy, bruising.
-Eye $\rightarrow$ viral infection, cataract, glaucoma.
-Inhalation $\rightarrow$ fungal infection, hoarseness.
-Intrarticular $\rightarrow$ infection, necrosis.
-Diabetes mellitus. -Hypertension or heart failure. -History of mental disorders or Epilepsy. -Osteoporosis. -Peptic ulcer. -Presence of infection or Tuberculosis $\rightarrow$ requires chemotherapy before administration.

## Precaution

1- Patients receiving GCs and is subjected to stress $\rightarrow$ double the dose, because it may lead to addisonian crisis .

2- In children receiving GCs $\rightarrow$ stop live attenuated vaccines, due to low immunity.
3- In pregnant women; better avoid fluorinated GCs (long acting GCs) $\rightarrow$ teratogenicity.

4- Neo-born to mothers taking high dose GCs $\rightarrow$-ve HPA axis $\rightarrow$ give the neo-born low dose of GCs the reduce it gradually to avoid adrenocortical insufficiency .
slide doctor's note important
explanation

## PHARMACOLOGY OF MINERALOCORTICOIDS

## Aldosterone natural（not given），Deoxycorticosterone（DOCA），Fludrocortisone

－Bind to mineralocorticoid receptors［binds GC＞MC］$\Rightarrow$ in Mineralocorticoids responsive cells i．e． distal nephron．
－GC is destroyed，enzymatically in MC responsive cells $\Rightarrow$ so MC will bind to its receptor alone without any competition from GC．

1．Cytosolic Mineralocorticoids receptor $\rightarrow$ mediates GENOMIC Action $\rightarrow$ Expression of proteins．
－In distal \＆collecting tubules：

- Na pumps $\rightarrow$ 个 Na retention
-Na channels $\rightarrow \uparrow \mathrm{Na}$ reuptake from lumen
$\bullet K$ simporters $\rightarrow$ 个 excretion of K \＆H．（＊N．B．Actions also on（colon，sweat \＆salivary glands））
2．Membranous GC R mediates NON－GENOMIC Action．
－Interact with GP coupled receptors \＆channels to mediate rapid adaptive changes to fluid depletion．


## －Fludrocortisone Drug of choice in replacement thereby

－DOCA given Sublingual ，ineffective orally．
－Net effect is to conserve body sodium $\rightarrow$ osmotic effect $\rightarrow$ water follows $\rightarrow$ expansion of extracellular fluid．
－个renal excretion of potassium $\& \downarrow$ intracellular potassium－
－In excess $\rightarrow$ hypertension，atherosclerosis ，fibrosis $\rightarrow$ vascular \＆cardiac remodeling $\rightarrow$ cerebral hemorrhage，stroke \＆or cardiomyopathy．

## Corticosteroid antagonist

| DRUG | M.O.A. | INDICATIONS | NOTES |
| :---: | :---: | :---: | :---: |
| METOTANE | Inhibit $\beta$-hydoxylase <br> $\rightarrow$ inhibit corticosteroid synthesis $\rightarrow \downarrow$ its peripheral metabolism \& plasma \& urine levels | Cushing syndrome: <br> - To reduce the symptoms before the surgery. <br> - If the surgery can't be performed. | Safe in pregnancy. |
| SPIRONOLACTONE <br> Aldosterone ntagonist | - K sparing diuretic. <br> - Compete with steroid on receptors to block MC action. | * Hypertension \& heart failure in hyperaldosteronism (Conn's) | - |

GLUCOCORTICOIDS


## Replacment thrapy

| Used in | Drugs | Notes |  |
| :--- | :--- | :--- | :--- |
| Addison's crisis | Cortisol (hydrocortisone) | Cause salt and water retention |  |
| Addison's disease | Cortisol <br> fludrocortisone | Minralocorticoid |  |
|  | Dexamethasone |  |  |
| Cushing | Dexamethasone <br> suppression test | In Diagnoses |  |
| syndrome | Cortisol | Temporally AFTER surgical removal of tumors |  |
| ANTI-INFLAMMATORY \& IMMUNOSUPPRESSANT |  |  |  |
| Drugs |  | uses |  |
| Prednisolone |  | Severe allergic reactions <br> Diseases of allergic origin, Autoimmune <br> disorders, Organ transplantation, Blood <br> dyscrasias, Acute gout |  |
| Dexamethasone |  | uses |  |
| Betamethasone |  | Raised I.C.P, neoplastic diseases, <br> With cytotoxic drugs |  |
| OTHERS |  |  |  |
| Dexamethasone |  |  |  |
| Betamethasone |  |  |  |



## MINERALOCORTICOIDS

| Drug | Therapeutic uses | Adverse effects |
| :--- | :---: | :---: |
| Aldosterone | Not used clinically | In excess $\rightarrow$ hypertension, <br> atherosclerosis fibrosis $\rightarrow$ <br> vascular \& cardiac <br> remodeling $\rightarrow$ cerebral <br> hemorrhage $/$ stroke $\&$ or <br> cardiomyopathy |
| Deoxycortone <br> sterone[DOCA] | - | Drug of Choice in <br> Replacement Therapy <br> In Addison's disease |
| Fludrocortisone |  |  |


| CORTICOSTEROID ANTAGONIST |  |  |
| :---: | :---: | :---: |
| Drug | Therapeutic uses | Notes |
| MITOTANE | - Cushing syndrome | - $\downarrow$ Glucocorticoids <br> - Safe in pregnancy |
| SPIRONOLACTONE | - hypertension <br> - heart failure <br> - Hyperaldosteronism (Conn's) | Block mineralocorticoids actions (aldosterone antagonist) |


| slide | doctor's note | important | explanation |
| :--- | :--- | :--- | :--- | :--- |

## Quiz yourself

Q1: Typical features of topical corticosteroid use in dermatology include all of the following, except: A) more potent corticosteroids should be preferred because of higher efficacy
B) Ointments are more potent than creams
C) occlusive dressing can help increase the potency of a topical corticosteroid D) corticosteroid are best used in areas where the skin is thin,e.g. Face, scrotum, etc.
E) systemic absorption always leads to adrenals suppression with topical corticosteroid therapy

Q6: Which one of the following is given with cortisol incase of chronic Addison's disease because it has a mineralocorticoid like action:
A) Hydrocortisone
acetate
B) Beclomethason
C) Fludrocortisone

Q2: Which one of the following is wrong about lipocortin
A) lipocortin inhibits PLA2, cox-2
B) activated GRs prevent AP-1 from binding to RE and expressing proinflamatory mediators as lipocortin
C) activated GRs dimerize and bind to GRE allowing expression of antiinflammatory mediators as lipocortin

> Q7: What would you do if you're treating your patient with Glucocorticoids and you know that he's subjected to stress:
> A) You lower the dose B) You ask the patient to not take the medication while he's in a bad mood C) You double the dose

Q3: child came to you with dermatitis in his face what is the topical treatment in this case?
A) Beclomethasone cream
B) Fluticasone cream C) Hydrocortisone acetate ointment

Q4: Patient came to ER with hyponatremia, hyperkalemia, hypoglycemia, fever, confusion, sever vomiting, diarrhea and shock.
Which one of the following drugs is used in this case?
A) Betamethasone
B) Triamcinolone
C) Cortisol

Q5: A 34-yr-old woman with ulcerative colitis has required long-term treatment with pharmacologic does of a glucocorticoid agonist. Which of the following is a toxic effect associated with long-term glucocorticoid treatment?
A) A " lupus-like" syndrome
B) Adrenal gland neoplasm
C) Osteoporosis

## Explanation for Q1

Explanation: Traditionally, topical corticosteroids are divided into classes based on their potency. There is not much difference in safety and efficacy if one agent is compared over other. However, there may be significant difference in price. Although ointments are more oily, they are also more potent than creams. At least 4 hours of occlusive dressing (gloves, plastic wrap) can lead to several-fold increase in the potency of a topical corticosteroid. On areas of thin skin including vulva, skin folds, ear canal besides face and scrotum, topical corticosteroids must be used with caution. Topical corticosteroid use on the eyelids is known to cause glaucoma and cataract. The amount of topical corticosteroid to be used can be calculated be the same "rule of nines" as done in patients with burns. In general, about $20-30 \mathrm{~g}$ steroid is required to cover the body surface of an adult at one time. It is well-known that systemic absorption of topically applied steroids does occur, but adrenal suppression, and other systemic complications like osteoporosis, diabetes, hypertension, etc. appear to be rare.

## THIS WORK WAS DONE BY:

Contact us for any questions or comments :

Pharma_433@yahoo.com
@pharma_433

Raneem Alotaibi Ahmed Aldakhil

Hanan Aldossari
Rawan Alyahya
Reem Almassoud

We hope that we made this lecture easier for you Good Luck!

